Laronde logo

Laronde Funding & Investors

Cambridge, MA

Laronde is pioneering a platform that offers a completely novel way of modulating human biology. Endless RNAβ„’ (eRNA), is a uniquely engineered RNA that can be programmed to express diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery. Laronde was founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering. The company is rapidly scaling to support the parallel development of multiple programs across many disease areas.

laronde.bio

Total Amount Raised: $490,000,000

Laronde Funding Rounds

  • Series B

    $440,000,000

    Series B Investors

    Flagship Pioneering
    CPP Investments
    Fidelity Investments
    Federated Kaufmann Fund
    T. Rowe Price
    Invus Group
    BlackRock
    LVF
  • Series A

    $50,000,000

    Series A Investors

    Flagship Pioneering
Funding info provided by Diffbot.